Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Millenium

- PMLiVE

GSK and Pfizer combine melanoma drugs in new trial

Will investigate effects of adding palbociclib to Mekinist

Roche - Basel

Roche cuts $1bn deal on cancer therapy with Immatics

Licenses series of early-stage oncology immunotherapy programmes

- PMLiVE

AstraZeneca moves MEK inhibitor selumetinib into phase III

Begins late-stage trials of its targeted lung cancer drug

- PMLiVE

New US drug discovery institute partners with Takeda

Tri-Institutional Therapeutics Discovery Institute to cover communicable, chronic and rare conditions

- PMLiVE

UK’s Cancer Drugs Fund given new lease of life

Government invests £400m and pledges Fund will remain until 2016

- PMLiVE

Merck Serono puts faith in lung cancer candidate

Continues tecemotide development despite underwhelming phase III results

- PMLiVE

Teva signs R&D alliance to pursue novel cancer drugs

Will work with Cancer Research on first-in-class oncology treatments

- PMLiVE

‘Biomedical Facebook’ launches to speed up cancer research

Europe's Granatum.org aims to connect pharma, academia and other research bodies

- PMLiVE

Takeda appoints new financial head

François-Xavier Roger brings experience from Sanofi and in telecoms

- PMLiVE

FDA grants priority review to Takeda’s colitis drug

Accelerates review time for vedolizumab

- PMLiVE

Takeda continues Actos resurrection as Alzheimer’s drug

Late-stage trial will see if pioglitazone can delay disease progression

Takeda expands Latin American footprint

Opens new subsidiary in Peru

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links